Department of Gynecologic Surgery, IEO European Institute of Oncology - IRCCS, Milano, Italy; Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Department of Gynecologic Surgery, IEO European Institute of Oncology - IRCCS, Milano, Italy.
Gynecol Oncol. 2021 Jul;162(1):38-42. doi: 10.1016/j.ygyno.2021.04.026. Epub 2021 Apr 24.
To evaluate the role of cervical re-injection of indocyanine green (ICG) to increase the detection rate of sentinel lymph node (SLN) in patients with endometrial cancer (EC) who underwent robotic-assisted surgical staging.
We retrospectively identified consecutive EC patients undergoing robotic-assisted staging with SLN biopsy at our Institution between June 2016 and April 2020. Patients were excluded if they had open abdominal surgical approach, neoadjuvant chemotherapy, and advanced stage [International Federation of Gynecology and Obstetrics (FIGO) stage III-IV] at diagnosis. According to our SLN protocol, in case of either unilateral or no SLN detection, we performed an ipsilateral or bilateral cervical re-injection of ICG.
In total, 251 patients meeting inclusion criteria were included in the analysis. At first injection, bilateral detection was achieved in 184 (73.3%), unilateral detection in 57 (22.7%), and no detection in 10 (4.0%) patients. Cervical re-injection was performed in 51 of 67 patients with failed bilateral mapping. After cervical re-injection, bilateral detection rate increased to 94.5% (222/235), while unilateral and no detection were 5.1% (12/235) and 0.4% (1/235), respectively.
Our results suggest that cervical re-injection of ICG, in case of failed bilateral mapping of SLN, brings about a significant improvement in SLN detection rates, therefore reducing the number of side-specific required lymphadenectomies.
评估在接受机器人辅助手术分期的子宫内膜癌(EC)患者中,颈内再注射吲哚菁绿(ICG)以提高前哨淋巴结(SLN)检测率的作用。
我们回顾性地确定了 2016 年 6 月至 2020 年 4 月期间在我院接受机器人辅助分期和 SLN 活检的连续 EC 患者。如果患者采用开腹手术、新辅助化疗和诊断时为晚期(国际妇产科联合会 [FIGO] 分期 III-IV 期),则将其排除在外。根据我们的 SLN 方案,如果出现单侧或无 SLN 检测,则对同侧或双侧行颈内 ICG 再注射。
总共纳入了 251 名符合纳入标准的患者进行分析。在首次注射时,184 名(73.3%)患者双侧检测,57 名(22.7%)患者单侧检测,10 名(4.0%)患者未检测。对 67 名双侧 SLN 定位失败的患者进行了颈内再注射。颈内再注射后,双侧检测率增加到 94.5%(222/235),单侧和无检测率分别为 5.1%(12/235)和 0.4%(1/235)。
我们的结果表明,在 SLN 双侧定位失败的情况下,颈内再注射 ICG 可显著提高 SLN 检测率,从而减少侧特异性淋巴结切除术的数量。